Structured evidence table for Sulforaphane Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sulforaphane Blood Pressure Randomized Trial | Substantial evidence has supported the beneficial role of healthy dietary factors in preventing the occurrence and development of CMDs and atherosclerosis in the aging population [,,,]. | 2 | Wu Qi (2026) | Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial |
| Sulforaphane Blood Pressure Randomized Trial | Therefore, we performed a 12-month cluster-randomized controlled intervention trial to evaluate the effects of the RCMDR dietary pattern on clustered cardiometabolic risk, common carotid artery (CCA) atherosclerosis parameters, CMD risk factors (blood lipids, blood glucose, insulin sensitivity, homocysteine (Hcy), blood pressure) and body composition in community-dwelling older adults. | 2 | Wu Qi (2026) | Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial |
| Sulforaphane Blood Pressure Randomized Trial | 13 The primary outcome was the clustered cardiometabolic disease risk score (CMRS), calculated in the same way as in previously published study using waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and fasting glucose (FBG)[]. | 2 | Wu Qi (2026) | Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial |
| Sulforaphane Blood Pressure Randomized Trial | [1] [2] [3] 4 5 3 6 [7] [8] [9] [10] Cardiometabolic diseases (CMDs), including a series of interrelated diseases, such as hypertension, diabetes, dyslipidemia, coronary heart disease and stroke, are the leading causes of death and disability worldwide and also pose a serious threat to the health of Chinese residents [,,]. | 2 | Wu Qi (2026) | Effects of a cardiometabolic risk–reducing dietary pattern health education intervention on cardiometabolic disease risk in community-dwelling older adults in China: a cluster-randomized clinical trial |
| Sulforaphane Blood Pressure Randomized Trial | Background/Objectives : Broccoli-derived glucoraphanin (a sulforaphane precursor that activates Nrf2 defenses) may aid repair; however, its short-term effects in humans remain unknown. | 2 | Cesanelli L (2026) | Short-Term Effects of Broccoli-Derived Glucoraphanin on Recovery from Eccentric Muscle Damage: A Double-Blind Randomized Crossover Study. |
| Sulforaphane Blood Pressure Randomized Trial | This study aimed to evaluate whether short-term supplementation with broccoli-derived glucoraphanin improves recovery from exercise-induced muscle damage. | 2 | Cesanelli L (2026) | Short-Term Effects of Broccoli-Derived Glucoraphanin on Recovery from Eccentric Muscle Damage: A Double-Blind Randomized Crossover Study. |
Source documents